Control of Alternative Splicing by Signal-dependent Degradation of Splicing-regulatory Proteins*

  1. Rebeccah J. Katzenberger,
  2. Matthew S. Marengo§1 and
  3. David A. Wassarman§2
  1. Department of Pharmacology and the §Molecular and Cellular Pharmacology Program, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53706
  1. 2 To whom correspondence should be addressed: University of Wisconsin School of Medicine and Public Health, Dept. of Pharmacology, 1300 University Ave., Madison, WI 53706. Tel.: 608-262-6648; Fax: 608-262-1257; E-mail: dawassarman{at}wisc.edu.

Abstract

Alternative pre-mRNA splicing is a major gene expression regulatory mechanism in metazoan organisms. Proteins that bind pre-mRNA elements and control assembly of splicing complexes regulate utilization of pre-mRNA alternative splice sites. To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT). The screen identified 15 proteins that, when knocked down, caused the same change in TAF1 alternative splicing as CPT treatment. However, combined RNA interference and CPT treatment experiments indicated that only a subset of the identified proteins are targets of the CPT-induced signal, suggesting that multiple independent pathways regulate TAF1 alternative splicing. To understand how signals modulate the function of splicing factors, we characterized one of the CPT targets, Tra2 (Transformer-2). CPT was found to down-regulate Tra2 protein levels. CPT-induced Tra2 down-regulation was ATR-dependent and temporally paralleled the change in TAF1 alternative splicing, supporting the conclusion that Tra2 directly regulates TAF1 alternative splicing. Additionally, CPT-induced Tra2 down-regulation occurred independently of new protein synthesis, suggesting a post-translational mechanism. The proteasome inhibitor MG132 reduced CPT-induced Tra2 degradation and TAF1 alternative splicing, and mutation of evolutionarily conserved Tra2 lysine 81, a potential ubiquitin conjugation site, to arginine inhibited CPT-induced Tra2 degradation, supporting a proteasome-dependent alternative splicing mechanism. We conclude that CPT-induced TAF1 alternative splicing occurs through ATR-signaled degradation of a subset of splicing-regulatory proteins.

Footnotes

  • 3 The abbreviations used are: snRNP, small nuclear ribonucleoprotein; CHX, cycloheximide; CPT, camptothecin; dsRNA, double-stranded RNA; GFP, green fluorescent protein; HA, hemagglutinin; hnRNP, heterogeneous ribonucleoprotein; IR, ionizing radiation; qPCR, quantitative real-time PCR; RNAi, RNA interference; RRM, RNA recognition motif; RS, arginine/serine-rich; SR, serine/arginine-rich; E3, ubiquitin-protein isopeptide ligase.

  • * This work was supported, in whole or in part, by National Institutes of Health Grant T32 GM08688 (to M. S. M.). This work was also supported by National Science Foundation Grants MCB-0614059 and MCB-0743403 (to D. A. W.) and by a predoctoral fellowship from the PhRMA Foundation (to M. S. M.).

  • Graphic The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1 and 2.

  • 1 Present address: Dept. of Molecular Genetics and Microbiology, Duke University, Medical Center, Durham, NC 27710.

    • Received December 18, 2008.
    • Revision received January 21, 2009.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement